RWE Oncology Market by Component, Application, End User - Global Forecast to 2029

Real-World Evidence (RWE) Oncology Market Worth $1.65 Billion by 2029

RWE Oncology Solutions Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer) - Global Forecast to 2029

The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029.

After a comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides insights into key industry drivers, restraints, challenges, and opportunities of the RWE oncology solutions market.

The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.

Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

Based on end user, in 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

An in-depth analysis of the geographical scenario of the RWE oncology solutions market provides detailed qualitative and quantitative insights into the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to command the largest share of the global RWE oncology solutions market, followed by Europe and Asia-Pacific.

Some of the key companies operating in the RWE oncology solutions market include IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report:

RWE Oncology Solutions Market, by Component

• Real-world Datasets
• Disparate Datasets
• EMR/EHR/Clinical Data
• Claims & Billing Data
• Pharmacy Data
• Cancer Registries
• Other Disparate Datasets
• Integrated Datasets
• Real-world Consulting & Analytics Services

RWE Oncology Solutions Market, by Application

• Drug Development & Approvals
• Market Access & Reimbursement/Coverage Decisions
• Post-market Surveillance
• Medical Device Development & Approvals
• Other Applications

RWE Oncology Solutions Market, by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

RWE Oncology Solutions Market, by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe (RoE)
• Asia-Pacific (APAC)
• Japan
• China
• India
• South Korea
• Taiwan
• Singapore
• Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa